- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04537936
Psychotherapy Intervention for Latinos With Adv Cancer
Adaptation and Pilot Feasibility of a Psychotherapy Intervention for Latinos With Advanced Cancer
Study Overview
Status
Detailed Description
Overview of the Study. This project has 5 phases. In phases 1 and 2 the study team will work to gain an understanding of the sources of meaning, hope, legacy and identity in Latino patients with advanced cancer; and to explore the acceptability and feasibility of applying IMCP to Latinos diagnosed with advanced cancer. A convergent mixed-methods design will be utilized with a sample of 200 Latino patients diagnosed with advanced cancer for the quantitative phase, and a nested cohort of 14-20 for the qualitative phase from two cancer centers in New York City: Memorial Sloan Kettering Cancer Center (MSKCC) and Lincoln Medical and Mental Health Center (LMC), a public hospital localized in a Latino-dense region. We will also recruit eligible cancer patients serviced through Dr. Gany's Integrated Cancer Care Access Network (ICCAN). The Integrated Cancer Care Access Network (ICCAN) of MSKCC's Immigrant Health and Cancer Disparities Service (IHCD) enrolls patients at eleven hospital-based cancer clinics in New York City with large numbers of immigrant and low-income patients. ICCAN uses bilingual Access Facilitators to assist patients in accessing and utilizing health, social, and financial services. Identified needs of the patients, range from psychosocial support, to health literacy, child care, financial, housing and legal concerns. Patients enrolled to the ICCAN program are actively obtaining support from Access Facilitators throughout their treatment period. Access Facilitator will refer eligible patients to the study team for recruitment.
Before moving to phase 3, we will adapt and transcreate (the source text is rewritten to convey the concepts and achieve the aims of the source text, while accounting for both language and cultural considerations) the manual based on the phase 1 and 2 findings. In the phase 3 (Key Informant feedback), mental health providers will be interviewed to explore additional needed adaptations.
Phase 4 will consist of pre-piloting or interviewing patients to assess the comprehension and acceptability of the adapted intervention. Patient Feedback phase, key components of the intervention will be pre-piloted with 6-10 patients across MSKCC and, Lincoln Medical and Mental Health Center (LMC)
Participants who express concerns or request assistance related to COVID-19 will be referred to publicly available resources as needed (e.g., call 311 for access to health care or food panties, etc.) and will be noted in internal tracking logs.
Phase 5 Randomized Controlled Pilot Study Phase will collect preliminary data on the feasibility of recruitment, retention and adherence and acceptability of content of Meaning-Centered Psychotherapy for Latinos (MCP-L) and key outcomes (spiritual well-being, depression, anxiety, hopelessness, and quality of life). Additional information will be collected, specifically scales measuring , attitudinal familism, acculturation, fatalism, religiosity, and literacy, which will inform the design of a future large-scale randomized clinical trial of the culturally adapted intervention. A sample of 60 Spanish-speaking advanced cancer patients will be enrolled and randomized evenly to MCP-L or to Enhanced Usual Care (EUC) control.
Eligible patients for Phase 5 will meet the same criteria as Phase 1 patients ; however patients who score > 4 on the Distress Thermometer will be recruited to Phase 5, and patients who score < 4 will be recruited to Phase 1.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rosario Costas-Muniz, PhD
- Phone Number: 646-888-8062
- Email: costasmr@mskcc.org
Study Contact Backup
- Name: William Breitbart, MD
- Phone Number: 646-888-0020
- Email: breitbaw@mskcc.org
Study Locations
-
-
-
Ponce, Puerto Rico, 00732
- Recruiting
- Ponce Health Sciences University
-
Contact:
- Eida Castro-Figueroa, PhD
- Email: ecastro@psm.edu
-
-
-
-
New York
-
Bronx, New York, United States, 10451
- Recruiting
- Lincoln Medical and Mental Health Center
-
Contact:
- Monica R Muppidi, MD
- Phone Number: 718-579-4900
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Rosario Costas-Muniz, PhD
- Phone Number: 646-888-8062
-
New York, New York, United States, 10035
- Recruiting
- MSK at Ralph Lauren
-
Contact:
- Rosario Costas Muniz, PhD
- Phone Number: 646-888-8062
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Phase I: Quantitative
- Diagnosed with stages III or IV solid tumor cancer *(as per self report for ICCAN patients)
- Age 18 or older
- As per self report, Latino/a or Hispanic ethnicity
- As per self report, fluent in oral Spanish (monolingual) or fluent in oral Spanish and English (bilingual)
Phase 2: Qualitative
- Enrolled in the quantitative phase of study (as seen above)
- Completes the quantitative phase questionnaire
- Scores above or below the threshold for the Distress Thermometer (DT≥4 or ≤3)
- In the judgment of the investigator, willing and able to be interviewed in Spanish only
- Agrees to be audio- recorded
Phase 3: Provider Feedback
- Professionals working in the mental health field;
- Have a caseload of five or more Latino cancer patients per month
- Able to communicate and read in Spanish
- Agrees to be audio or video-recorded
Phase 4: Patient Feedback
- Diagnosed with stages III or IV solid tumor cancer *(as per self report for ICCAN patients)
- Age 18 or older
- As per self report, Latino/a or Hispanic ethnicity
- In the judgment of the investigator, willing and able to be interviewed in Spanish only
- Agrees to be audio-recorded
Phase 5: Pilot RCT
- Diagnosed with stages III or IV solid tumor cancer
- Age 18 or older
- Latino/a or Hispanic ethnicity
- Fluent in oral Spanish (monolingual or bilingual)
- Scores above the threshold for the Distress Thermometer (DT≥4)
- Agrees to be audio-recorded
Exclusion Criteria:
Phase 1: Quantitative
- In the judgment of the treating physician and/or the consenting professional, presence of significant cognitive impairment (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection
- In the judgment of the consenting professional, significant or major disabling medical or psychiatric condition sufficient to preclude meaningful informed consent, interview, or completion of assessment measures (patients whose psychiatric disorder is well controlled by treatment will be eligible)
Phase 2: Qualitative
- In the judgment of the treating physician and/or the consenting professional, presence of significant cognitive impairment (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection
- In the judgment of the consenting professional, significant or major disabling medical or psychiatric condition sufficient to preclude meaningful informed consent, interview, or completion of assessment measures (patients whose psychiatric disorder is well controlled by treatment will be eligible)
Phase 4: Patient Feedback
- Diagnosed with a major disabling medical or psychiatric condition
- Unable to understand the consent procedure
- Too ill to participate, all as reported by the patient and/or determined by the investigator's judgment.
Phase 5: Pilot RCT
- Diagnosed with a major disabling medical
- Diagnosed with a major disabling psychiatric condition
- Unable to understand the consent procedure
- Too ill to participate, all as reported by the patient and/or determined by the investigator's judgment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control
|
Determines the degree of spiritual well-being
Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
MCP-L consists of seven-60 minute-individual sessions.
The seven sessions are expected to be delivered every week or every two weeks over a span of 7-14 weeks.
Other Names:
|
Experimental: Meaning Centered Psychotherapy for Latinos (MCP-L)
|
Determines the degree of spiritual well-being
Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
MCP-L consists of seven-60 minute-individual sessions.
The seven sessions are expected to be delivered every week or every two weeks over a span of 7-14 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Spiritual Well-Being measured with the FACIT Spiritual Well-Being Scale
Time Frame: Change from baseline to post assessment 7-14 weeks after
|
FACIT Spiritual Well-Being Scale is a brief self-report measure designed to assess the nature and extent of individual spiritual well-being.
This measure, which generates two sub-scales, one corresponding to Faith (the importance of faith and spirituality) and a second assessing Meaning-Peace (one sense of meaning and purpose in life), has been demonstrated to have strong internal reliability for both the total score as well as each subscale (coefficient alpha equals .87 for the total scale, .88 for the faith factor and .81
for the meaning factor).
In additional, strong support for the external validity of this measure has been demonstrated in a several large samples of cancer and AIDS patients and with Spanish speaking populations.
|
Change from baseline to post assessment 7-14 weeks after
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Depression and Anxiety measured with the Hospital Anxiety and Depression Scale
Time Frame: Change from baseline to post assessment 7-14 weeks after
|
The Hospital Anxiety and Depression Scale (HADS) is a validated scale used to measure anxiety and depression.
This scale has been validated against structured or semi-structured clinical interviews, the gold standard for the assessment of mental disorders, in a significant number of studies.
Further strengths of this scale for the assessment of emotional distress in cancer patients stem from the joint assessment of anxiety and depressive symptoms without referring to physical symptoms of anxiety or depression.
Given the high comorbidity of anxiety of cancer as well as the systematic exclusion of confounding physical symptoms, the scale seems especially appropriate for use in this patient group.
The HADS consists of 14 items which reflect a 7-item anxiety and a 7-item depression subscale.
This scale has sound psychometric properties in Spanish.
|
Change from baseline to post assessment 7-14 weeks after
|
Hopelessness measured with the Beck Hopelessness Scale
Time Frame: Change from baseline to post assessment 7-14 weeks after
|
The Beck Hopelessness Scale (BHS) comprises 20 true/false questions that assess degree of pessimism and hopelessness.
Several studies have demonstrated a high degree of internal consistency and construct validity.
Scores ranging from 4 to 8 typically indicate a "mild" degree of hopelessness, 9 to 12 correspond to "moderate" hopelessness, and scores about 12 reflect "severe" levels of hopelessness.
|
Change from baseline to post assessment 7-14 weeks after
|
Quality of life measured with the FACIT Spiritual Well-Being Scale
Time Frame: Change from baseline to post assessment 7-14 weeks after
|
The FACIT Spiritual Well-Being Scale (FACIT-Sp-12) is a brief self-report measure designed to assess the nature and extent of individual's spiritual well-being.
This measure (range 0-48), which generates two sub-scales, Faith (the importance of faith/spirituality, range 0-16) and Meaning /Peace (one's sense of meaning and purpose in life, range 0-32).
The total score for the FACIT-Sp scale is the sum of the two subscales Faith and Meaning /Peace.
It has been demonstrated to have strong internal reliability for both the total score as well as each subscale (coefficient alpha = .87
for the total scale, .88 for the faith factor and .81
for the meaning factor).
Higher scores represent a higher level of spiritual well-being, faith or meaning-peace.
In addition, strong support for the external validity of this measure has been demonstrated in a several large samples of cancer and AIDS patients and with Spanish speaking populations.
Administration time takes approximately 4 minutes.
|
Change from baseline to post assessment 7-14 weeks after
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Rosario Costas-Muniz, PhD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-076A(20)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
-
Daiichi SankyoRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States, Japan
Clinical Trials on Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterAstellas Pharma Inc; Medivation, Inc.Active, not recruitingBreast Cancer | Triple Negative Breast Cancer | Early StageUnited States
-
Memorial Sloan Kettering Cancer CenterUniversity of Texas Southwestern Medical Center; Wake Forest UniversityActive, not recruitingBreast CancerUnited States
-
Massachusetts General HospitalClinical GenomicsWithdrawnGastrointestinal MalignanciesUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingMalignant Biliary ObstructionUnited States
-
Washington University School of MedicineCompleted
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); National...CompletedLymphoma | Plasma Cell MyelomaUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingMelanoma | Kidney Cancer | Breast Cancer | Gastric Cancer | Lung Cancer | Bladder Cancer | Skin Cancer | Head Neck CancerItaly
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Lung Cancer | Anxiety DisorderUnited States
-
Memorial Sloan Kettering Cancer CenterComprehensive Cancer Centre The NetherlandsRecruitingCancer | Dermatologic ConditionsUnited States